Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel, with no reliable method to identify at-risk patients. We investigated the incidence and risk factors including genetic polymorphisms associated with the development of CIPN based on clinician and patient reporting of neuropathic symptoms.
Introduction
Paclitaxel (Taxol) results in peripheral nerve damage in up to 70% of ovarian cancer patients, with moderate to severe symptoms in 20% [1] . Chemotherapy-induced peripheral neuropathy (CIPN) impacts on fine motor function and balance, leading to a threefold increase in falls risk [2] . Importantly, CIPN affects physical, functional and emotional well-being and quality of life (QOL) in ovarian cancer patients [3] . This may persist long term, with ovarian cancer survivors reporting neuropathic symptoms 12 years after treatment, which were negatively associated with quality of life [4] .
Clinician-based grading scales are widely used to record neuropathy severity both in routine clinical practice and trials but are limited by inter-observer variability and under-reporting of significant symptoms [5] . Accordingly, patient-reported outcomes (PROs) are increasingly utilised to appreciate the incidence, trajectory and impact of CIPN from the perspective of the patient. However, there remains a lack of consensus regarding appropriate CIPN outcome measures and in particular whose opinion should take precedence.
Accurate assessment of toxicity severity is critical to the successful identification of risk factors associated with CIPN. The lack of reliable and well validated assessment tools has contributed to discordance between studies of clinical and genetic risk factors [6] . There are currently no reliable predictors to identify patients at greater risk of developing persistent neurotoxicity. While a number of genetic polymorphisms have been investigated, contributions to paclitaxel-induced neurotoxicity are likely polygenic [7] . Paclitaxel alters microtubule dynamics and stabilization, which may be important in neuropathy development [8] . Accordingly, single nucleotide polymorphisms (SNPs) in microtubule-associated genes have been associated with paclitaxel [9, 10] and vincristine-induced neuropathy [11] .
The International Collaboration on Ovarian Neoplasms 7 (ICON7) trial of paclitaxel/carboplatin chemotherapy with or without bevacizumab included two methods of assessing CIPN, enabling comparison between clinician and patient-reported neuropathy. The aim of this study was to investigate the association between clinician and patient-reported neurotoxicity with demographic and putative genetic risk factors.
Methods

Patients and study design
The study was undertaken using clinical data and peripheral blood DNA samples from the ICON7 trial, a multicentre, phase III trial undertaken in 1528 patients with ovarian cancer [12] . Details of the trial methods, results and quality-of-life outcomes for the entire cohort have been reported previously [12] [13] [14] . ICON7 translational research samples were provided following peer review and approval by the translational research subgroup and trial steering committee. All patients provided written informed consent. The protocol was approved by Independent Ethics Committees and in accordance with the Declaration of Helsinki. Only ICON7 patients providing consent for translational research sample collection and matched DNA and clinical data were available for this analysis (N ¼ 454 patients). In ICON7, patients with stage 1 to 4 epithelial ovarian cancer were randomised to receive six cycles of three weekly carboplatin (area under the curve 5 or 6) and paclitaxel (175 mg/m 2 ) with or without bevacizumab (7.5 mg/ kg) [12] . Patients with pre-existing Grade !2 neuropathy were excluded from the trial. Grade !2 neuropathy required paclitaxel delay until resolution to grade 1 (National Cancer Institute Common Toxicity Criteria Version grading below grade 2-Moderate symptoms; limiting instrumental ADL and grade 3-Severe symptoms; limiting self care ADL), followed by dose reduction. Grade 3 neuropathy required paclitaxel cessation.
Outcome measures
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3 Neuropathy Sensory subscale was used by clinicians to report neuropathy severity. The European Organisation for Research and Treatment of Cancer quality of life questionnaire-ovarian cancer module (EORTCQLQ-OV28) provided paper-based data on patient-reported neuropathy [15] , utilising two questions: 'Have you had tingling hands or feet?' and 'Have you had numbness in your fingers or toes?' Patients scored symptoms within the past week on a four-point scale corresponding to 'not at all', 'a little', 'quite a bit' and 'very much'. High scores represent greater symptom burden. Outcome measures were collected at each treatment cycle followed by 6 weekly assessments for 36 weeks. Follow-up assessment was undertaken at 15 and 18 months post-treatment commencement.
Polymorphism selection and assessment DNA samples were obtained from the ICON7 biobank (University of Leeds, UK). Analysis was restricted to patients of Caucasian ancestry due to differences in allele frequencies, as per prior studies [16] . Six microtubule-associated polymorphisms were selected for analysis based on effects on microtubule dynamics: microtubule associated protein tau (MAPT; rs242557 and rs1052553 [17] ), glycogen synthase kinase-3 beta (GSK3B; rs6438552 and rs3755557 [16] ), CEP72 rs924607 [11] and b-tubulin (TUBB2; rs909961 [18] ). Polymorphisms were genotyped using TaqMan Probe Genotyping Assays (Thermo Fisher Scientific, Waltham). Genotypes were scored to reflect their effects on gene transcription-alleles associated with lower expression were assigned values of '0' and opposing alleles assigned '1'. Additive effects of polymorphisms within the same gene were examined by a sum score. Additional details provided in supplementary methods, available at Annals of Oncology online.
Statistical analysis
Patient demographics were summarised as percentages if categorical and medians/means if continuous variables. Clinician-reported neuropathy (CRN) was considered to be significant if NCI-CTCAE grade !2. Significant patient-reported neuropathy (PRN) was based on a response of 'quite a bit' or 'very much' on either neuropathy-related question of the EORTC QLQ-OV28 scale. CRN duration was based on dates of adverse events recorded during study visits. Neuropathy was considered persistent if there was no documented resolution by 18-month followup. The j statistic was used to determine agreement between PRN and CRN. For polymorphism analysis, deviation from Hardy-Weinberg equilibrium was tested with chi-square tests (supplementary Table S1 , available at Annals of Oncology online). Wilcoxon signed rank tests were utilised to examine differences between groups with and without bevacizumab. Proportional hazards regression models modelled the cumulative dose to first incidence of neuropathy (dose-to-event analysis). Patients who did not experience significant neuropathy were censored at their final cumulative dose. Kaplan-Meier curves were constructed to demonstrate probability of neuropathy in relation to cumulative dose. The univariate association of baseline demographics with CIPN was investigated using proportional hazards models. All associations with P < 0.1 were used as candidate variables for a multivariable model with stepwise selection procedure. P values <0.05 were considered statistically significant. No correction for multiple testing was undertaken, in light of the exploratory analyses, which should be considered when interpreting the results. Analyses were conducted using SPSS and Stata version 13.
Results
The baseline characteristics of the 454 patients are displayed in Table 1 and were comparable to the ICON7 intention-to-treat population. Majority of patients in this analysis (388 patients; 85.5%) received six cycles of paclitaxel/carboplatin treatment. Median paclitaxel dose was 1050 (range, 175-1155) mg/m 2 . One hundred and sixty five patients (36%) required at least one (4) 27 (4) 8 (4) 7 (3) Primary peritoneal 56 (7) 50 (6) 13 (6) 20 (9) Multiple sites 12 (2) 14 (2) 4 (2) 7 (3) Histology, n (%) Serous 529 (69) 525 (69) 151 (69) 160 (68) Mucinous 15 (2) 19 (2) 3 (1) 2 (1) Endometrioid 57 (7) 60 (8) 17 (8) 15 (6) Clear cell 60 (8) 67 (9) 23 (11) 30 (13) Mixed 48 (6) 40 (5) 13 (6) 21 (9) Other 55 (7) 53 (7) 12 (5) 7 (3) FIGO stage, n (%) I/IIA 75 (10) 67 (9) 23 (11) 19 (8 
Comparing clinician and patient reports
The incidence of PRN was significantly higher than CRN, with low agreement between PRN and CRN [j ¼ 0.236, 95% confidence interval (CI), 0.177-0.296, P < 0.001; Table 2; Figure 1 ]. Patients (30.6%) were assigned a maximum CRN grade of zero (N ¼ 139), while only 13.9% of patients (N ¼ 63) reported never experiencing PRN. Further, patients reported neuropathic symptoms earlier than clinician reported neuropathy-with onset by the third cycle in 45% of patients (N ¼ 152) compared with 17% of patients as reported by clinicians (N ¼ 79). The incidence of first events of PRN was consistently higher than CRN over cumulative paclitaxel doses; 9% versus7% at 500 mg, 33% versus 18% at 1000 mg, 50% versus 25% at 1500 mg and 83% versus 34% at 2000 mg. Of patients who required paclitaxel dose reduction or cessation due to neuropathy, 81.8% (27/33) were classified as grade !2 CRN, while 97.0% (32/33) reported 'quite a bit' or 'very much' tingling or numbness. However, only 11.7% of patients (32/274) who reported 'quite a bit' or 'very much' tingling or numbness received a paclitaxel dose reduction.
Predictors of CRN
Older age was associated with greater risk of significant CRN in univariable dose-to-event analyses [hazard ratio (HR), 1.03, 95% CI, 1.01-1.05, P ¼ 0.003; Table 3 ) as was bowel resection (HR, 2.58, 95% CI, 1.39-4.79, P ¼ 0.003) and treatment with bevacizumab (HR, 1.47; 95% CI, 1.02-2.10, P ¼ 0.04). In multivariable analyses, older age (HR, 1.04, 95% CI, 1.02-1.06, P < 0.001), bowel resection (HR, 2.71, 95% CI, 1.41-5.20, P ¼ 0.003), and bevacizumab (HR, 1.73, 95% CI, 1.19-2.52, P ¼ 0.004) remained significantly associated with risk of CRN.
In line with these results, patients with significant CRN were older (58.8 6 9.7 years) compared with those without (56.1 6 9.4 years; supplementary Table S3 , available at Annals of Oncology online). 61.1% of patients with significant CRN received bevacizumab (N ¼ 77), while 48.5% of patients without CRN received bevacizumab (N ¼ 159). There was no difference in demographic variables such as age or paclitaxel dose between patients treated with and without bevacizumab. The distribution of neuropathy events was similar across treatment arms, but a higher proportion of patients experienced CRN during or after cycle 6 in the bevacizumab group. In total, 20 patients underwent bowel resectionof these 11 patients developed grade !2 CRN, while 9 patients did not develop significant neuropathy.
Predictors of PRN
In univariable modelling, PRN was associated with older age at baseline (HR, 1.02, 95% CI, 1.00--.03, P ¼ 0.01; Patients with significant PRN were older (57.3 6 9.6 years) compared with those without significant PRN (55.9 6 9.5 years). Of the patients with significant PRN, 2.6% had inoperable disease (N ¼ 8), while 5.4% of patients without PRN had inoperable disease (N ¼ 8).
Genetic predictors of neuropathy status
DNA analyses were restricted to 424 patients of Caucasian ancestry. There were no significant associations between CRN or PRN and TUBB2, CEP72 or individual MAPT or GSK3B SNPs (supple mentary 
Discussion
In the present study, paclitaxel was associated with significant and long-lasting neuropathy, with considerable discordance identified between patient and clinician reports of neuropathy. Given the lack of substantive agreement between patient-and clinician-reported neuropathy in the present study, it is not surprising that there was often little overlap between clinical and genetic risk factors. These findings raise the important question of whether patient rather than clinician-reported toxicities are more appropriate measures of CIPN in studies investigating predictors such as genetic polymorphisms and risk of neuropathy.
While we identified significant discrepancy between CRN and PRN, the rates of CRN during treatment were consistent with previous studies [1, 19] . Prior studies reported 1-year probability of residual CRN of 24%-33% [19, 20] , similar to our finding of 27.3%. In contrast, PRN was evident in 90.6% of patients and did not resolve by 18-month follow-up in a significant proportion (54%). Likewise, a substantial proportion of paclitaxel-treated patients report ongoing PRN (50%-60%) in the 3 to 6 years after treatment [4, 21] . Although a limitation of our study is that the cohort is a subset of the entire intention-to-treat ICON7 population, this suggests that the cohort is likely comparable to the wider population. Further, quality of life analyses in 890 ICON7 patients at 12-months follow-up indicated that PRN persisted in a broader ICON7 cohort, with average neuropathy corresponding to 'quite a bit' on the OV28 scale [14] . These findings underscore the importance of including patient-reported adverse effects to provide comprehensive patient-centred assessment of CIPN. Direct comparison of PROs and clinician-based toxicity ratings have demonstrated poor to moderate agreement across a range of adverse effects, with patients often reporting more severe symptoms [22] . Although there is similarity between CIPN severity reported by clinicians and patients [23, 24] , low concordance has been identified in previous reports [25, 26] , similar to the current study. The reasons for this are multifactorial and include the detailed scope of PROs, improved sensitivity and responsiveness to change [23, 24] . Clinician-based grading scales are limited by a lack of sensitivity and inter-observer reliability which may further impact on comparability to PROs [5] . Additionally, future studies that examine the use of tools such as balance and gait assessments to provide objective evidence of neuropathic dysfunction [27] will assist to improve replication and validation in risk factor analyses.
Risk factors associated with the development of neuropathy differed between CRN and PRN, suggesting that careful examination of CIPN outcome measures is required to accurately ascertain risk factors. Older age was associated with both CRN and PRN in dose-to-event analyses. Older age has previously been Original article Annals of Oncology identified as a risk factor for CIPN in taxane-treated patients with 4% increased odds of neuropathy per year [28] or 13% increased risk of CIPN per decade [6] , respectively, identified in different cohorts. Older age has also been associated with neuropathy persistence [29] . CRN was also linked to bowel resection and PRN was associated with the volume of residual disease following debulking surgery. These factors have not previously been linked to neuropathy and may instead reflect association with other patient characteristics. CRN was associated with bevacizumab treatment, which as a single agent is not associated with significant neuropathy [30] . Concomitantly with paclitaxel, bevacizumab was associated with greater neuropathy in ovarian cancer patients in the AURELIA trial although the discrepancy was attributed to longer chemotherapy exposure in bevacizumab-treated patients [31] . The addition of bevacizumab to carboplatin/paclitaxel treatment did not significantly alter the proportion of ovarian cancer patients with neuropathy in GOG218 [29] . Bevacizumab has been associated with increased risk of neuropathy in conjunction with paclitaxel in metastatic breast cancer [32] , also related to higher response rates and longer duration of treatment. However, a retrospective study of metastatic breast cancer patients treated with bevacizumab and paclitaxel demonstrated increased risk of severe neuropathy with bevacizumab despite the same duration of treatment [33] . In contrast, a reduced risk of neuropathy with bevacizumab in addition to paclitaxel/cisplatin has been reported in cervical cancer [34] . Detailed examination of the potential role of bevacizumab in exacerbating paclitaxelinduced neuropathy is warranted. In addition, it should be noted that carboplatin is an independently neurotoxic chemotherapy [35] and may contribute to the present neurotoxicity profile.
PRN was linked to additive MAPT SNPs in dose-to-event analyses, while CRN was linked to additive GSK3B SNPs. The MAPT polymorphisms rs242557 and rs1052553 increase MAPT transcription and hence tau production [16] . Increased tau expression may promote paclitaxel binding to microtubules [36] and enhance stabilisation which could exacerbate the impact of paclitaxel on microtubule function and axonal transport. Likewise, GSK3B rs6438552 was associated with reduced risk of CRN in a prior study [10] and functions to increase tau phosphorylation, effectively reducing microtubule stability [37] . While these associations remained significant in multivariable analyses, there may also be additional functional polymorphisms relevant to patient phenotyping, which should be examined in further cohorts with appropriate outcome measures.
Prior studies have identified SNPs in other microtubuleassociated genes linked to CIPN. TUBB2A SNPs (rs909964, rs909965) were protective against paclitaxel-induced neuropathy [9] but not in a separate cohort [38] or in docetaxel-treated patients [39] . In the present study, TUBB2A SNP rs909961 (highly correlated with rs909964; SNP Annotation and Proxy Search) did not demonstrate association with PRN or CRN. Similarly, CEP72 (rs924607) was previously linked to vincristine-induced CIPN [11] although not in all cohorts [40] and not in the present analysis. These findings underscore the difficulties in comparing neurotoxicity risk across different patient cohorts. Selection of phenotyping tools is a central issue in CIPN polymorphism studies. Predominantly clinicianbased toxicity grading has been utilised to define neuropathy in prior studies, although exclusive use of CTCAE toxicity scales in pharmacogenomic studies has been identified as leading to poor reproducibility and reliability [41] . There have been difficulties in validation of SNPs as risk factors for CIPN across multiple cohorts [6, 42] , potentially due to differential assessment methods and differences in case identification.
Our findings demonstrate that variability between CIPN grading between studies, particularly with regards to PRO selection, may contribute to the discordance between studies examining CIPN risk factors. Further, discordance between clinician and PRN may impact on paclitaxel dose reduction and delays in treatment, with unknown long-term consequences. The fundamental question remains as to whose opinion counts more -patients or clinicians? PROs are an essential component to future analyses of CIPN, particularly in studies of genetic risk factors. These results also underscore the importance of standardised assessment protocols for CIPN in order to enable identification of patients at risk of persistent neuropathy and to facilitate trials of interventions to prevent neuropathy.
